Thus, a Bcl‐XL inhibitor (e.g. A1331852) or dual Bcl‐2/Xl inhibitor (such as ABT263) should be tested with FGFR inhibitors in other FGFR‐dependent tumour models in order to determine the feasibility of a basket trial testing this combination in multiple FGFR‐dependent malignancies. The gene discussed is BCL2L1; the disease is neoplasm.